Background: Previous metoprolol studies in myocardial infarction patients were performed with immediate-release (IR) metoprolol. This study aims to evaluate if extended-release metoprolol CR/XL once daily gives a similar β-blockade over 24 h compared to multiple dosing of metoprolol IR. Methods: After 2 days of routine metoprolol treatment, 27 patients with suspected acute myocardial infarction were randomized to open-label treatment with metoprolol IR (50 mg four times daily or 100 mg twice daily) or metoprolol CR/XL 200 mg once daily for 3 days. Results: Metoprolol CR/XL 200 mg once daily gave more pronounced suppression of peak heart rate, with lower peak and less variation in peak to trough plasma levels. There were no differences in AUC between the CR/XL and IR formulations, although the trough plasma metoprolol levels were comparable for metoprolol CR/XL 200 mg once daily and metoprolol IR 50 mg four times daily, but lower for metoprolol IR 100 mg twice daily. Both treatments were well tolerated. Conclusions: Metoprolol CR/XL 200 mg once daily showed lower peak and less variation in peak to trough plasma levels compared to multiple dosing of metoprolol IR with the same AUC. This was accompanied by a more uniform β-blockade over time, which was reflected by heart rate, and a more pronounced suppression of peak heart rate with similar tolerability. This suggests metoprolol CR/XL may be used as an alternative to metoprolol IR in patients with myocardial infarction.

Keywords:
β-Blockade, Extended release formulations, Heart rate, Metoprolol, Myocardial infarction
1.
The Norwegian Multicenter Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
2.
β-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-1714.
3.
Hjalmarson Å, Herlitz J, Malek I, Rydén L, Vedin A, Waldenström A, Wedel H, Elmfeldt D, Holmberg S, Nyberg G, Swedberg K, Waagstein F, Waldenström J, Wilhelmsen L: Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet 1981;2:823-827.
4.
Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T: Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-1437.
5.
Salathia KS, Baber JM, McIllmoyle EL, Nicholas J, Evans AE, Elwood JH, Cran G, Shanks RG, Boyle DM: Very early intervention with metoprolol in suspected acute myocardial infarction. Eur Heart J 1985;6:190-198.
6.
Magner Cats V, van Capelle FJL, Lie KI, Durrer D: The Amsterdam metoprolol trial. Effect of treatment with metoprolol on first-year mortality in a single-centre study with low placebo mortality rate after myocardial infarction. Drugs 1985;29(suppl 1):8.
7.
Lopressor Intervention Trial Research Group: The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987;8:1056-1064.
8.
Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, Hjalmarson Å, Sonnenblick EH: Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
9.
Herlitz J, Dellborg M, Karlson BW, Lindqvist J, Sandèn W, Svensson H, Sjölin M, Wedel H: Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc Drugs Ther 1999;13:127-135.
10.
The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985;6:199-226.
11.
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS, COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction) collaborative group: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-1632.
12.
Held PH, Regårdh CG: Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study. Eur J Clin Pharmacol 1986;31:261-265.
13.
Sandberg A, Blomqvist I, Jonsson UE, Lundborg P: Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988;33(suppl):S9-S14.
14.
Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J: Design of a new multiple-unit controlled-release formulation of metoprolol - metoprolol CR. Eur J Clin Pharmacol 1988;33(suppl):S3-S7.
15.
Balmèr K, Zhang YY, Lagerström PO, Persson BA: Determination of metoprolol and two major metabolites in plasma and urine by column liquid chromatography and fluorometric detection. J Chromatogr 1987;417:357-365.
16.
Lucker P, Moore P, Wieselgren I, Olofsson B, Bergstrand R: Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990;30(suppl 2):S17-S27.
17.
Andersson B, Åberg J, Lindelöw B, Täng MS, Wikstrand J: Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. J Card Fail 2001;7:311-317.
18.
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C, Task Force On Beta-Blockers of the European Society of Cardiology: Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-1362.
19.
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction): ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.